Navigation Links
Use of Fractional Flow for Optimizing Patient Outcomes is Topic of Several Sessions at TCT 2007
Date:10/19/2007

Radi Medical Systems Sponsors Case Review with Drs. Morton Kern, Nico

Pijls, Augusto Pichard

UPPSALA, Sweden and WILMINGTON, Mass., Oct. 19 /PRNewswire/ -- The use of fractional flow reserve (FFR) for optimizing patient outcomes is the topic of several sessions at this year's Transcatheter Cardiovascular Therapeutics symposium, TCT 2007, which will take place Oct. 20-25 in Washington.

Radi Medical Systems AB, the first company to develop systems that calculate FFR with the physiologic assessment of targeted lesions, is sponsoring a breakfast session, Nine Cases That Will Change Your Practice: FFR Case Review, at 7 a.m. EDT on Oct. 23 in room No. 152 B in the Washington Convention Center. Morton J. Kern, M.D., of the University of California- Irvine, is the session's moderator, while Nico Pijls, M.D., Ph.D. of Catharina Hospital, Eindhoven, the Netherlands, and Augusto Pichard, M.D., of the Washington Hospital Center, are the participating faculty.

In addition to coverage in the case review, FFR and physiologic lesion assessment are the subject of:

-- An extensive workshop at 2 p.m. on Oct. 21 that will focus on the

basics of FFR measurement, the use of FFR in specific settings, and the

practicalities and impact of FFR in the era of drug-eluting stents

(Room 147AB)

-- A session on Oct. 22 during the "Board Review Course with Self

Assessment for Interventional Cardiology and Endovascular Medicine,

PART 3: Coronary Essentials" that will cover IVUS and physiologic

lesion assessment in clinical practice and physiologic lesion

assessment case presentations with an integrated Q&A (Room 146AB)

About FFR

FFR expresses maximum achievable blood flow in a coronary artery with abnormal stenosis as a fraction of normal maximum blood flow in the absence of a stenosis. It is calculated using an interventional guidewire with a specially designed sensor built into it. Using the well established value of 0.75, FFR is 100% specific in identifying which lesions are actually causing flow restriction and can be treated. FFR also documents the exact percentage of the reduction in flow associated with each lesion.

About Radi Medical Systems AB

Radi Medical Systems AB (Radi) develops, manufactures and sells medical devices designed to improve patient care. The company's pioneering work in the field of interventional cardiology has resulted in market-leading intravascular sensors and hemostasis management and radiology devices. Radi works closely with medical practitioners to develop solutions that address clinical needs, as well as provide clinical education support. Founded in 1988, Radi employs more than 350 people globally and has representation in more than 40 countries. The company is based in Uppsala, Sweden, and maintains a U.S. headquarters in Wilmington, Mass. For more information, visit http://www.radi.se.

Editor's Note: Radi Medical Systems will display its latest products at booth No. 2085 at TCT 2007.

Media Contacts:

David Schull or Benjamin Carmichael

Russo Partners

+1 212-845-4271

+1 858-717-2310 (during TCT 2007)

david.schull@russopartnersllc.com

benjamin.carmichael@russopartnersllc.com

Jim Archetto

Radi Medical Systems

+1 877-337-7234 ext. 812

jim.archetto@radi.se


'/>"/>
SOURCE Radi Medical Systems AB
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
2. Optimizing pfuturbo DNA Polymerase Amplification Reactions with Perfect Match PCR Enhancer
3. Optimizing electroporation parameters
4. Optimizing Büchi® Rotary Evaporator Applications
5. Optimizing electroporation parameters
6. Optimizing Büchi® Rotary Evaporator Applications
7. Optimizing Bchi Rotary Evaporator Applications
8. Optimizing electroporation parameters
9. Optimizing electroporation parameters
10. Optimizing electroporation parameters
11. Optimizing electroporation parameters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... 22, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced ... will present at the 5th Annual Cancer BioPartnering ... platform to present to and meet with thought ... biotech companies as well as institutional investors. This ...
(Date:3/20/2017)... ... ... and Whitehouse Laboratories, divisions of Albany Molecular Research, Inc, are looking forward to ... (PDA), the New York Interphex Show will open on March 21 and run through ... the educational and networking opportunities are extremely valuable. INTERPHEX is viewed as the key ...
(Date:3/20/2017)... ... March 20, 2017 , ... ... biotech companies, recently announced it will debut a brand new pressure vessel, the ... intelliVessel is controlled by a touch screen panel and features other revolutionary operations ...
(Date:3/20/2017)... ... March 20, 2017 , ... Existing methods using LC-MS/MS ... order to reduce the impact on instrumentation. ICP-MS is a robust and specific ... , This presentation will discuss the pros and cons of using LC-ICP-MS ...
Breaking Biology Technology:
(Date:2/28/2017)... , February 28, 2017 News solutions for ... ... from 14 to 16 March, Materna will present ... show how seamless travel is a real benefit for passengers. ... biometrics to their passenger touch point solutions to take passengers through ...
(Date:2/22/2017)... -- With the biometrics market to exceed $10 ... that innovative and agile startups must incorporate into ... changing competitive landscape: multifactor authentication (MFA), point-of-sale (PoS), ... "Companies can no longer afford to cut corners ... Pavlakis , Industry Analyst at ABI Research. "Pairing ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
Breaking Biology News(10 mins):